We had earlier reported on why 2018 was the year of healthcare IPOs. It seems the trend is continuing into this year as well. Two healthcare unicorns have already priced their IPOs this year, and both of them happened this week.
San Diego-based biotech firm Gossamer Bio, which focuses on immunology and oncology drugs, priced 17.25 million shares late on Thursday at $16 apiece.
The company, which has three experimental drugs under development, raised $276 million through the initial public offering. The stock started trading on Nasdaq under the symbol GOSS on Friday.
Bank of America Merrill Lynch, Evercore ISI, Barclays and SVB Leerink were the underwriters of the public listing.
The biotech unicorn, which is headed by former Receptos executive Sheila Gujrathi, will use the raised amount to advance its flagship asthma drug, as well as other investigational therapies.
On Wednesday, South San Francisco-based Alector priced 9.25 million shares at $19 apiece, raising $176 million in the first IPO since the 35-day federal government shutdown. The stock, which started trading on Nasdaq under the ticker ALEC on Thursday, ended the day over 5% in red.
Also read: These 2 tech startups may follow Spotify’s method of direct listing over IPO in 2019
Notably, Alector specializes in brain disorders and approaches Alzheimer’s Disease as an immune system disorder. The company, which is headed by former Genentech scientist Arnon Rosenthal, will use the net proceeds to develop new drugs as well as for the clinical trials of the experimental ones.
Alector had earlier raised funding from Amgen Inc, Abbvie and GV (Google Ventures). Bank of America, Barclays, Cowen Inc, and Morgan Stanley were the underwriters of the IPO.
We’re on Flipboard! Follow us to receive the latest stock market, earnings and financial news at your fingertips
Most Popular
Can General Motors (GM) navigate the tariff challenge ahead?
General Motors' (NYSE: GM) stock tumbled last week after the Trump administration imposed new tariffs on automobile imports, raising concerns about their potential impact on the company’s production as it
What to look for when Delta Air Lines (DAL) reports its Q1 2025 earnings results
Shares of Delta Air Lines (NYSE: DAL) were down over 1% on Monday. The stock has dropped 28% over the past three months. The airline is scheduled to report its
STZ Earnings Preview: Can Constellation Brands leverage growing beer sales?
Constellation Brands, Inc. (NYSE: STZ) has effectively navigated challenges like cautious consumer spending and declining demand for its wine and spirits brands by capitalizing on the sustained growth in the
